212Pb α-Radioimmunotherapy Targeting CD38 in Multiple Myeloma: A Preclinical Study.
Ontology highlight
ABSTRACT: Multiple myeloma (MM) is a plasma cell cancer and represents the second most frequent hematologic malignancy. Despite new treatments and protocols, including high-dose chemotherapy associated with autologous stem cell transplantation, the prognosis of MM patients is still poor. α-radioimmunotherapy (α-RIT) represents an attractive treatment strategy because of the high-linear-energy transfer and short pathlength of α-radiation in tissues, resulting in high tumor cell killing and low toxicity to surrounding tissues. In this study, we investigated the potential of α-RIT with 212Pb-daratumumab (anti-hCD38), in both in vitro and in vivo models, as well as an antimouse CD38 antibody using in vivo models. Methods: Inhibition of cell proliferation after incubation of the RPMI822
SUBMITTER: Quelven I
PROVIDER: S-EPMC7383085 | biostudies-literature | 2020 Jul
REPOSITORIES: biostudies-literature
ACCESS DATA